期刊文献+

HPLC法测定人红细胞中次黄嘌呤鸟嘌呤磷酸核糖转移酶活性 被引量:6

Activity Determination of Hypoxanthine Guanine Phosphoribosyl Transferase in Human Red Cells by HPLC
下载PDF
导出
摘要 目的:建立一种检测次黄嘌呤鸟嘌呤磷酸核糖转移酶(HGPRT)活性的高效液相色谱法,并检测患者红细胞中HGPRT活性。方法:在5-磷酸核糖-1-焦磷酸(PRPP)条件下,HGPRT催化次黄嘌呤生成次黄嘌呤核苷酸(IMP),高氯酸沉淀蛋白后进行高效液相色谱法分析。采用Hypersil ODS C_(18)(150 mm×4.6 mm,5μm)柱;流动相为磷酸氢盐缓冲液-乙腈(99.6:0.4),流速1 ml·min^(-1),在262 nm处检测IMP。应用新建立的高效液相色谱法测定68例服用过硫唑嘌呤的肾移植患者红细胞中HGPRT活性。结果:在该条件下,测得的线性范围是20~600μmol·L^(-1),检测限是20μmol·L^(-1),其日间和日内精密度均小于5%,方法回收率和提取回收率分别在100.81%~101.91%和99.05%~101.40%范围内。65例患者红细胞HGPRT活性范围为44.59~123.86 U,平均(87.83±21.55)U。结论:该法操作简便、灵敏度高、重复性好,适用于临床常规检测。 Objective : To develop an assay method for the activity determination of hypoxanthine guanine phosphoribosyl transfer- ase(HGPRT) in human red cells by HPLC. Method: In the presence of 5-phosphorylribosel pyrophosphate (PRPP), hypoxanthine was changed into hypoxanthine nucleotide (IMP) under the catalysis of HGPRT. The sample was deposited by perchloric acid and then analyzed by HPLC. A Hypersil ODS Cl8 (150 mm × 4.6 mm,5 μm) column was used. The mobile phase was potassium phosphate buffer-acetonitrile (99.6: 0.4) and the flow rate was 1 ml min-l. The detection wavelength of IMP was 262 nm. The HGPRT activity in the red cells of 68 kidney transplantation patients treated by azathioprine was detected. Result: The standard curve was linear within the range of 20-600μmol L-l , and LLOQ was 20μmol L-1. The intra- and inter-day preeisions were both less than 5% , and the method recovery and the extraction recovery was 100.81% -101.91% and 99.05 % -101.40% , respectively. The HGPRT activity range of 65 patients was 44.59-123.86 U with the average value of ( 87.83 ± 21.55 ) U. Conclusion : The method is simple, sensitive and repeatable, which is applicable in the HGPRT activity detection in the clinical practice.
出处 《中国药师》 CAS 2013年第2期196-199,共4页 China Pharmacist
关键词 次黄嘌呤鸟嘌呤磷酸核糖转移酶 活性 高效液相色谱法 Hypoxanthine guanine phosphoribosyl transferase Activity HPLC
  • 相关文献

参考文献11

  • 1Elion GB Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues[ J]. Fed Proc, 1967, 26 : 898-904.
  • 2Weber G. Biochemical strategy of cancer cells and the design of chem- otherapy: G. H. A. Clowes Memorial Lecture[J]. Cancer Res,1983, 43 : 3466-92.
  • 3Sahasranaman S, Howard D, Roy S. Clinical pharmacology and phar- macogenetics of thiopurines[ J]. Eur J Clin Pharmacol, 2008,64(8) : 753-767.
  • 4熊晖,辛华雯,熊磊,吴笑春,李罄,李高.肾移植受者红细胞ITPA活性与硫唑嘌呤不良反应关系的研究[J].中国药理学通报,2008,24(11):1496-1500. 被引量:2
  • 5Leese HJ. Profiles of hypoxanthine guanine phosphoribosyl transferase and adenine phosphoribosyl transferase activities measured in single preimplantation human Embryos by high-performance liquid chromatog- raphy[ J]. Repord Fert, 1991,91 : 197-202.
  • 6Van Asseldonk DP. Limited intra-individual variability in hypoxan- thine-guanine phosphoribosyl transferase, thiopurine s-methyl transfer- ase,and xanthine oxidase activity in inflammatory bowel disease pa- tients during 6-thioguanine therapy [ J ]. Nucleosides, Nucleotides and Nucleic Acids, 2010,29:284-290.
  • 7Someren H, Heneguuwen HB. Rapid detection of hypoxanthine- gua- nine phosphoribosyhransferase on cellogel [ J 1. Httmangenetik, 1974, 22, 75-80.
  • 8Krenitsky TA, Papaioannou R, Elion GB. Human hypoxanthine phos- ph-oribosyltransferase. I Purification, properties and specificity [ J . J Biol Chem, 1969, 244 : 1263-1270.
  • 9Johnson LA, Gordon RB, Emmerson BT. Hypoxanthine-guanine phos- phoribosyhransferase: A simple spectro-photometricassay [ J ]. Clin Chim Acta, 1977,80 : 203-207.
  • 10Wong PCP, Hey Y, Fowler JSL. A fluorometric assay of the phosphoryl- ation of 6-mercaptopurine in human blood cells [ J ]. Clin Chim Acta, 1979,99 : 43-51.

二级参考文献19

  • 1Vanderheiden B S. Purification and properties of human erythrocyte inosine triphosphate pyrophosphohydrolase [ J ]. J Cell Physiol, 1979,98(1) :41 -7.
  • 2Shipkova M, Lorenz K, Oellerich M, et al. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase ( ITPA ) activity by HPLC and correlation of ITPA genotype-phenotype in a caucasian population[J]. Clin Chem,2006,52(2):140-7.
  • 3Maeda T, Sumi S, Ueta A, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population [J]. Mol Genet Metab ,2005 ,85( 4 ) :271 -9.
  • 4Lennard L. TPMT in the treatment of Crohn's disease with azathioprine [ J ]. Gut,2002,51 (2) : 143 - 6.
  • 5Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy andad- verse drug reactions in patients within flammatory bowel disease: impact of thiopurine S-methyhransferase polymorphism [ J ]. Pharmacgenetics, 2002,12 (6) :429 - 36.
  • 6Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in in Xammatory bowel disease [ J ]. Aliment Pharmacol Ther,2002,16 (10) : 1743 - 50.
  • 7Kirschner B S. Salty of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease [ J ]. Gastroenterology,1998,115(4) :813 -21.
  • 8Marinaki A M, Ansari A, Duley J A, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPA) [ J ]. Pharmacogenetics ,2004,14( 3 ) : 181 - 7.
  • 9Marinaki A M, Ansari A, Duley J A, et al. Mutation in the ITPA gene predicts intolerance to azathioprine [ J ]. Nucleosides Nucleotides Nucleic Acids ,2004,23(8-9) :1393 -7.
  • 10Formea C M, Myers-Huentelman H, Wu R, et al. Thiopurine S- methyltransferase genotype predict azathioprine-induced myelotoxicity inkidney transplant recipients [ J ]. Am J Transplant, 2004,4 (11) :18t0-7.

共引文献1

同被引文献41

  • 1吴笑春,熊晖,熊磊,苏丹,辛华雯,李罄.肾移植受者硫嘌呤甲基转移酶基因多态性与硫唑嘌呤不良反应关系的研究[J].中国临床药理学与治疗学,2008,13(9):1037-1043. 被引量:3
  • 2袁晓环,佟丽华,赵洪涛.高效液相色谱测定水蛭药材次黄嘌呤的含量[J].牡丹江医学院学报,2006,27(1):68-70. 被引量:9
  • 3崔小兵,李伟,张科卫,蔡皓,吴皓.HPLC测定海龙中次黄嘌呤及黄嘌呤含量[J].中国海洋药物,2006,25(2):58-60. 被引量:12
  • 4李坚,龙晓英,何琳,刘芳,舒洁倩.HPLC测定不同产地广地龙中次黄嘌呤的含量[J].中药材,2006,29(5):448-449. 被引量:16
  • 5苏建平,许筠,翟晓丽.蛭龙胶囊对临床糖尿病肾病的疗效观察[C].甘肃省中医药学会2010年会员代表大会暨学术年会论文汇编.2010.260-261.
  • 6Alan KF, Sally A, Coulthard, et al. Thiopurines: factors influencing toxicity and response[J]. Br J Clin Pharmacol,2009,68(1) : 120-123.
  • 7Kudo M. Genetic variations in the HGPRT, ITPA, IMPDH1, IMPDH2, and GMPS genes in japanese individuals[J]. Drug Metab Pharmacokinet, 2009,24 (6) : 557-564.
  • 8Hindorf U, Lindqvist M, Peterson C, et al. Pharma- cogenetics standardised initiation of thiopurine treatment in infarmmatory bowel disease[J]. Gut, 2006,55 (10) : 1423-14231.
  • 9Sch wabM, Sehaeffeler E, Marx C, et al. Shor tcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotying only [J]. Gastroenterology, 2001, 121(2) : 498-499.
  • 10Evans WE, Hon YY, Bomgaars L, et al. Prepon- derance of thiopurine S -methy -lransferase deficien- cy and heterozygosity amon g patients intolerant to mercaptopurine or azathioprine[J]. J Clin Oncol, 2001, 19(8) : 2293-2301.

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部